Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Systemic Idiopathic Juvenile Arthritis Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Systemic Idiopathic Juvenile Arthritis Overview | 8 | 1 |
| Systemic Idiopathic Juvenile Arthritis Therapeutics under Development by Companies | 9 | 1 |
| Systemic Idiopathic Juvenile Arthritis Pipeline Products Glance | 10 | 3 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Systemic Idiopathic Juvenile Arthritis Products under Development by Companies | 13 | 1 |
| Systemic Idiopathic Juvenile Arthritis Companies Involved in Therapeutics Development | 14 | 8 |
| Alteogen Inc. | 14 | 1 |
| Bristol-Myers Squibb Company | 15 | 1 |
| Epirus Biopharmaceuticals, Inc. | 16 | 1 |
| Johnson &Johnson | 17 | 1 |
| Momenta Pharmaceuticals, Inc. | 18 | 1 |
| Mycenax Biotech Inc. | 19 | 1 |
| Novartis AG | 20 | 1 |
| Oncobiologics, Inc. | 21 | 1 |
| Systemic Idiopathic Juvenile Arthritis Therapeutics Assessment | 22 | 9 |
| Assessment by Monotherapy Products | 22 | 1 |
| Assessment by Target | 23 | 2 |
| Assessment by Mechanism of Action | 25 | 2 |
| Assessment by Route of Administration | 27 | 2 |
| Assessment by Molecule Type | 29 | 2 |
| Drug Profiles | 31 | 28 |
| abatacept Drug Profile | 31 | 5 |
| abatacept biosimilar Drug Profile | 36 | 1 |
| abatacept biosimilar Drug Profile | 37 | 1 |
| adalimumab biosimilar Drug Profile | 38 | 2 |
| adalimumab biosimilar Drug Profile | 40 | 1 |
| adalimumab biosimilar Drug Profile | 41 | 1 |
| adalimumab biosimilar Drug Profile | 42 | 1 |
| canakinumab Drug Profile | 43 | 5 |
| golimumab Drug Profile | 48 | 8 |
| tocilizumab biosimilar Drug Profile | 56 | 1 |
| tocilizumab biosimilar Drug Profile | 57 | 1 |
| tocilizumab biosimilar Drug Profile | 58 | 1 |
| Systemic Idiopathic Juvenile Arthritis Dormant Projects | 59 | 1 |
| Systemic Idiopathic Juvenile Arthritis Discontinued Products | 60 | 1 |
| Systemic Idiopathic Juvenile Arthritis Product Development Milestones | 61 | 10 |
| Featured News &Press Releases | 61 | 1 |
| Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis | 61 | 1 |
| Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris | 62 | 1 |
| May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis | 63 | 1 |
| Dec 19, 2012: Novartis's ACZ885 Significantly Relieves Symptoms In Patients With Serious Form Of Childhood Arthritis In Phase III Trials | 64 | 2 |
| Nov 08, 2012: Bristol-Myers Squibb To Present New Investigational Data On Orencia At 2012 American College Of Rheumatology Annual Scientific Meeting | 66 | 1 |
| Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012 | 67 | 2 |
| Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis | 69 | 2 |
| Appendix | 71 | 2 |
| Methodology | 71 | 1 |
| Coverage | 71 | 1 |
| Secondary Research | 71 | 1 |
| Primary Research | 71 | 1 |
| Expert Panel Validation | 71 | 1 |
| Contact Us | 71 | 1 |
| Disclaimer | 72 | 1 |